Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, early stage

1512 - Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s refined classification (TNBCtype-4).


09 Sep 2017


Breast cancer, early stage


Cytotoxic Therapy;  Breast Cancer


Isabel Echavarria Diaz-Guardamino


Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362


I. Echavarria Diaz-Guardamino1, A.C. Picornell2, S. López-Tarruella2, Y. Jerez2, K. Hoadley3, E. Alvarez2, M. del Monte-Millán2, J. Gayarre2, R. Ramos-Medina2, T. Massarrah1, I. Ocaña2, M. Cebollero4, F. Moreno Antón5, J.A. García-Saenz5, H. Gomez Moreno6, H. Fuentes6, A.I. Ballesteros Garcia7, U. Bohn Sarmiento8, C. Perou3, M. Martin Jimenez2

Author affiliations

  • 1 Medical Oncology, Hospital General Universitario Gregorio Marañon, 28007 - Madrid/ES
  • 2 Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañon (IiSGM), 28007 - Madrid/ES
  • 3 Genetics, University of North Carolina - Chapel Hill, 27599 - Chapel Hill/US
  • 4 Pathology, Hospital General Universitario Gregorio Marañon, 28007 - Madrid/ES
  • 5 Medical Oncology, Hospital Universitario Clínico San Carlos, Madrid/ES
  • 6 Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas - INEN, Lima 34 - Lima/PE
  • 7 Medical Oncology, Hospital Universitario de La Princesa, 28006 - Madrid/ES
  • 8 Medical Oncology, Hospital de Gran Canaria Dr. Negrin, 35020 - Las Palmas/ES


Abstract 1512


Triple-negative breast cancer (TNBC) is an aggressive subtype of BC in need for predictive biomarkers of response to neoadjuvant chemotherapy (NACT). We aimed to evaluate the predictive value of the TNBCtype-4 classifier in a population of TNBC treated with carboplatin and docetaxel (TCb).


Patients with stage I-III TNBC (ER and PR 


RNAseq was available for 94 of the 121 patients enrolled. Patients included had a median age at diagnosis of 51 years (range 28-78), 69.1% had nodal involvement and 52.1% and 46.8% had stage II and III disease, respectively. pCR rate and pathological good response (pCR or RCBI) were 44.7% and 56.4%. TNBCtype-4 distribution was: 34.0% BL1, 20.2% BL2, 23.4% M and 14.9% LAR. An additional 7.4% were classified as ER-positive. BL1 was associated with a significant younger age at diagnosis and higher ki67 values. TNBCtype-4 showed a significant association with response to NACT (p = 0.027), even in multivariate analysis including tumor size and nodal status, with BL1 patients achieving the highest pCR rate (65.6%), followed by BL2 (47.4%). Conversely, LAR and ER-positive showed the lowest pCR rates, 21.4% and 14.3%. When compared to BL1, LAR and M subtypes had an OR of achieving a pCR of 0.14 and 0.30 respectively (p 


TNBCtype-4 shows a significant predictive value of response in a TNBC cohort homogeneously treated with TCb, with BL1 and LAR displaying the best and worse responses to NACT respectively.

Clinical trial identification


Legal entity responsible for the study

Hospital General Universitario Gregorio Marañon


Institute of Health Carlos III (PI12-02684)


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.